Crystalline form of benzylbenzene SGLT2 inhibitor

1. A crystalline form of the compound of the formula:

characterized by an X-ray powder diffraction (XRPD) pattern that comprises peaks at 11.2, 12.9, 15.5, 17.8, 19.1, 20.0 and 20.7 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuK α1 radiation.

2. The crystalline form in accordance with claim 1 , characterized by an XRPD that further comprises one or more peaks at 5.4, 11.3, 11.9, 16.3, 20.6, 21.2, 22.8, 23.0, 23.4, 23.6, 23.9, 24.7, 25.4, 25.8, 27.8 and 28.2 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuK α1 radiation.

3. The crystalline form in accordance with claim 2 , characterized by an XRPD that comprises peaks at 11.2, 12.9, 15.5, 17.8, 19.1, 20.0, 20.6, 20.7, 21.2 and 22.8 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuK α1 radiation.

4. The crystalline form in accordance with claim 2 , characterized by an XRPD that comprises peaks at 5.4, 11.2, 11.9, 12.9, 15.5, 16.3, 17.8, 19.1, 20.0 and 20.7 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuK α1 radiation.

5. The crystalline form in accordance with claim 1 , characterized by an XRPD that comprises peaks at 5.4, 10.7, 11.2, 11.3, 11.9, 12.9, 14.7, 15.0, 15.5, 16.1, 16.3, 17.8, 18.7, 19.1, 20.0, 20.6, 20.7, 21.2, 21.6, 22.4, 22.8, 23.0, 23.4, 23.6, 23.9, 24.7, 25.4, 25.8, 27.0, 27.5, 27.8, 28.2, 28.9, 29.0 and 29.6 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuK α1 radiation.

6. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises one or more peaks at about 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm −1 .

7. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about 353, 688, and 825 cm −1 .

8. The crystalline form in accordance with claim 1 , characterized by a Raman spectra that comprises peaks at about 144, 189, 216, 226, 284, 315, 353, 387, 419, 432, 449, 503, 530, 565, 594, 638, 688, 716, 728, 755, 790, 825, 850, 884, 901, 919, 934, 974, 984, 1014, 1030, 1052, 1070, 1120, 1134, 1178, 1205, 1212, 1229, 1302, 1323, 1343, 1380, 1422, 1438, 1457, 1572, 1585, 1608, 2844, 2919, 2945, 2963, 2997, 3010, 3028, 3051, 3063, 3085, and 3095 cm −1 .

9. The crystalline form in accordance with claim 1 , characterized by

an XRPD that further comprises one or more peaks at 5.4, 11.3, 11.9, 16.3, 20.6, 21.2, 22.8, 23.0, 23.4, 23.6, 23.9, 24.7, 25.4, 25.8, 27.8 and 28.2 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuK α1 radiation; and

a Raman spectra that comprises one or more peaks at about 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm −1 .

10. The crystalline form in accordance with claim 1 , characterized by

an XRPD that further comprises one or more peaks at 20.6, 21.2, 22.8 and 28.2 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuK α1 radiation; and

a Raman spectra that comprises one or more peaks at about 353, 688, and 825 cm −1 .

11. The crystalline form in accordance with claim 1 , characterized by a differential scanning calorimetry (DSCI) endotherm at about 136° C.

12. The crystalline form in accordance with claim 1 , characterized by the following unit cell data:

Family and Space Group

Monoclinic P2 1 (#4)

Z’/Z

1/2

a (Å)

7.960

b (Å)

8.860

c (Å)

16.560

α (deg)

90

β (deg)

95.71

γ (deg)

90

Volume (Å 3 /cell)

1162.1

V/Z (Å 3 /asym. unit)

581.1

Assumed Composition

C 24 H 29 O 7 Cl

Density (g/cm 3 )

1.329

Weight Fraction Solvent (%)

N/A.

13. The crystalline form of the compound of claim 1 which is isotopically labeled.

14. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the crystalline form of the compound in accordance with claim 1 .